Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals

Junjie Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiujun Cai(Zhejiang University)
Cell Death and Disease
October 12, 2017
Cited by 73


Related Papers